ProCE Banner Activity

GS-US-380-1474: Switch to BIC/FTC/TAF Safely Maintains Virologic Suppression at Week 48 in Children and Adolescents With HIV Infection

Slideset Download
Conference Coverage
No drug-related serious adverse events and PK exposures comparable to adults with single-tablet regimen BIC/FTC/TAF in patients 6 to < 18 years of age.

Released: March 11, 2019

Expiration: March 09, 2020

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by independent educational grants from

Gilead

Gilead Text

Janssen

Merck Human Health HIV

ViiV Healthcare